Flexion Therapeutics, Inc. (FLXN): Price and Financial Metrics
FLXN Price/Volume Stats
|Current price||$9.12||52-week high||$13.66|
|Prev. close||$9.14||52-week low||$4.30|
|Day high||$9.23||Avg. volume||1,177,479|
|50-day MA||$7.97||Dividend yield||N/A|
|200-day MA||$8.28||Market Cap||458.93M|
FLXN Stock Price Chart Interactive Chart >
Flexion Therapeutics, Inc. (FLXN) Company Bio
Flexion Therapeutics focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. The company was founded in 2007 and is based in Burlington, Massachusetts.
FLXN Latest News Stream
|Loading, please wait...|
FLXN Latest Social Stream
View Full FLXN Social Stream
Latest FLXN News From Around the Web
Below are the latest news stories about Flexion Therapeutics Inc that investors may wish to consider to help them evaluate FLXN as an investment opportunity.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ECHO, ACBI, HRC, FLXN; Shareholders are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:Echo Global Logistics, Inc. (NASDAQ:ECHO)concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to funds managed by The Jordan Company, L.
Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark
Pacira's (PCRX) earnings beat estimates in the third quarter of 2021 while revenues miss the same. Its flagship product Exparel's sales rise year over year.
Pacira BioSciences, inc (PCRX) Q3 2021 Earnings Call Transcript
Joining me as speakers on today's call are Dave Stack, Chairman and Chief Executive Officer; and Charlie Reinhart, Chief Financial Officer. Before we begin, let me remind you that today's call will include forward-looking statements based on current expectations, including those related to the potential transaction between Pacira and Flexion Therapeutics.
FLEXION THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Flexion Therapeutics, Inc. - FLXN
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Flexion Therapeutics, Inc. (NasdaqGM: FLXN) to Pacira BioSciences, Inc. (NasdaqGS: PCRX). Under the terms of the proposed transaction, shareholders of Flexion will receive only $8.50 in cash and one non-tradable contingent value right (CVR) worth up to $8.00 per share in cash (assuming certain conditions are met) for each share of Flexion that
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ACBI, GTS, ADTN, COLB, DSPG, FLXN; Shareholders are Encouraged to Contact the Firm
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
FLXN Price Returns
Continue Researching FLXNWant to do more research on Flexion Therapeutics Inc's stock and its price? Try the links below:
Flexion Therapeutics Inc (FLXN) Stock Price | Nasdaq
Flexion Therapeutics Inc (FLXN) Stock Quote, History and News - Yahoo Finance
Flexion Therapeutics Inc (FLXN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...